KR102951376B1 - Dll3에 대한 키메라 수용체 및 이의 사용 방법 - Google Patents

Dll3에 대한 키메라 수용체 및 이의 사용 방법

Info

Publication number
KR102951376B1
KR102951376B1 KR1020207032081A KR20207032081A KR102951376B1 KR 102951376 B1 KR102951376 B1 KR 102951376B1 KR 1020207032081 A KR1020207032081 A KR 1020207032081A KR 20207032081 A KR20207032081 A KR 20207032081A KR 102951376 B1 KR102951376 B1 KR 102951376B1
Authority
KR
South Korea
Prior art keywords
gly
ser
delete delete
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207032081A
Other languages
English (en)
Korean (ko)
Other versions
KR20210018797A (ko
Inventor
마이클 존 기핀
멜리사 토마스
크리스토퍼 무라프스키
라이언 벤자민 케이스
로렌 우
제드 윌트지우스
루벤 알바레즈 로드리게즈
준 펭
Original Assignee
암젠 인크
카이트 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크, 카이트 파마 인코포레이티드 filed Critical 암젠 인크
Publication of KR20210018797A publication Critical patent/KR20210018797A/ko
Application granted granted Critical
Publication of KR102951376B1 publication Critical patent/KR102951376B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207032081A 2018-04-10 2019-04-10 Dll3에 대한 키메라 수용체 및 이의 사용 방법 Active KR102951376B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655725P 2018-04-10 2018-04-10
US62/655,725 2018-04-10
PCT/US2019/026840 WO2019200007A1 (en) 2018-04-10 2019-04-10 Chimeric receptors to dll3 and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20210018797A KR20210018797A (ko) 2021-02-18
KR102951376B1 true KR102951376B1 (ko) 2026-04-13

Family

ID=66248863

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032081A Active KR102951376B1 (ko) 2018-04-10 2019-04-10 Dll3에 대한 키메라 수용체 및 이의 사용 방법

Country Status (27)

Country Link
US (1) US12012462B2 (https=)
EP (1) EP3773912A1 (https=)
JP (1) JP7479290B2 (https=)
KR (1) KR102951376B1 (https=)
CN (1) CN112334193A (https=)
AR (1) AR114283A1 (https=)
AU (2) AU2019251473A1 (https=)
BR (1) BR112020020857A2 (https=)
CA (1) CA3095920A1 (https=)
CL (3) CL2020002613A1 (https=)
CO (1) CO2020013392A2 (https=)
CR (1) CR20200539A (https=)
EA (1) EA202092417A1 (https=)
IL (1) IL277735A (https=)
JO (1) JOP20200259A1 (https=)
MA (1) MA52203A (https=)
MX (1) MX2020010753A (https=)
MY (1) MY203383A (https=)
PE (1) PE20211396A1 (https=)
PH (1) PH12020551671A1 (https=)
SA (1) SA520420301B1 (https=)
SG (1) SG11202009923TA (https=)
TW (1) TWI842703B (https=)
UA (1) UA129466C2 (https=)
UY (1) UY38182A (https=)
WO (1) WO2019200007A1 (https=)
ZA (1) ZA202006943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
EP4527466A3 (en) 2019-07-17 2025-06-18 Legend Biotech Ireland Limited Anti-dll3 chimeric antigen receptors and uses thereof
JP2023504884A (ja) * 2019-12-05 2023-02-07 ヴィセリックス・インコーポレーティッド ユニバーサル細胞療法のための免疫逃避機構のモジュレーター
CN115298223A (zh) 2020-03-12 2022-11-04 南京传奇生物科技有限公司 磷脂酰肌醇蛋白聚糖-2结合部分、嵌合抗原受体及其用途
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
EP4313081A4 (en) * 2021-04-02 2025-04-09 Nanjing Legend Biotech Co., Ltd. MANIPULATED IMMUNE CELLS AND THEIR USES
MX2023012614A (es) * 2021-05-08 2023-11-03 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd Molecula de union contra dll3 y uso de la misma.
IL307646A (en) * 2021-05-10 2023-12-01 Amgen Inc Dosing regimen for combination therapy targeting DLL3 and PD-1
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
KR20240153604A (ko) 2022-03-03 2024-10-23 캠브리지 엔터프라이즈 리미티드 치료용 항체
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
AU2024347905A1 (en) * 2023-09-26 2026-04-02 Legend Biotech Ireland Limited Dll3 binding moieties and uses thereof
WO2025082340A1 (zh) * 2023-10-16 2025-04-24 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
GB202402046D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
GB202402048D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025202653A1 (en) 2024-03-27 2025-10-02 Ucl Business Ltd T-cell therapy targetting mutant calreticulin
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
GB202412771D0 (en) 2024-08-30 2024-10-16 Cambridge Entpr Ltd Therapeutic molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
JP2018506981A (ja) * 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３キメラ抗原受容体および使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
ES2654060T3 (es) * 2011-10-20 2018-02-12 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Receptores de antígenos quiméricos anti-CD22
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
AU2015214145A1 (en) 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
IL262061B2 (en) * 2016-04-01 2023-03-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018506981A (ja) * 2015-02-23 2018-03-15 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｄｌｌ３キメラ抗原受容体および使用方法
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3

Also Published As

Publication number Publication date
EP3773912A1 (en) 2021-02-17
CN112334193A (zh) 2021-02-05
EA202092417A1 (ru) 2021-01-26
MX2020010753A (es) 2021-01-29
UA129466C2 (uk) 2025-05-07
JP2021520788A (ja) 2021-08-26
IL277735A (en) 2020-11-30
SG11202009923TA (en) 2020-11-27
UY38182A (es) 2019-10-31
CR20200539A (es) 2021-07-01
MY203383A (en) 2024-06-26
PE20211396A1 (es) 2021-07-27
AU2019251473A1 (en) 2020-10-22
MA52203A (fr) 2021-02-17
JOP20200259A1 (ar) 2020-10-11
KR20210018797A (ko) 2021-02-18
CL2023000895A1 (es) 2023-11-03
US20210163621A1 (en) 2021-06-03
SA520420301B1 (ar) 2024-08-05
US12012462B2 (en) 2024-06-18
ZA202006943B (en) 2025-08-27
WO2019200007A1 (en) 2019-10-17
AR114283A1 (es) 2020-08-12
AU2026200393A1 (en) 2026-04-09
BR112020020857A2 (pt) 2021-01-19
CL2020002613A1 (es) 2020-12-28
TWI842703B (zh) 2024-05-21
JP7479290B2 (ja) 2024-05-08
CL2023000896A1 (es) 2023-11-03
PH12020551671A1 (en) 2021-06-07
CA3095920A1 (en) 2019-10-17
CO2020013392A2 (es) 2020-11-10
TW202011999A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
KR102951376B1 (ko) Dll3에 대한 키메라 수용체 및 이의 사용 방법
AU2022200108B2 (en) Chimeric receptors to FLT3 and methods of use thereof
KR102608405B1 (ko) 키메라 수용체 및 그의 사용 방법
KR102584280B1 (ko) 키메라 항원 및 t 세포 수용체 및 사용 방법
KR102591930B1 (ko) Bcma 결합 분자 및 그의 사용 방법
KR102914114B1 (ko) Steap1에 대한 키메라 수용체 및 이의 사용 방법
KR20220050948A (ko) 입양 세포 치료요법을 위한 면역 세포
TW202304962A (zh) 用於嵌合抗原受體細胞之組合式人造細胞死亡/報告系統多肽及其用途
HK40057006A (en) Chimeric receptors and methods of use thereof
HK40006441B (zh) 嵌合受体及其方法和用途
HK40000650B (en) Bcma binding molecules and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000